28129375|t|Mammary Gland Pathology Subsequent to Acute Infection with Strong versus Weak Biofilm Forming Staphylococcus aureus Bovine Mastitis Isolates: A Pilot Study Using Non-Invasive Mouse Mastitis Model
28129375|a|Biofilm formation by Staphylococcus aureus is an important virulence attribute because of its potential to induce persistent antibiotic resistance, retard phagocytosis and either attenuate or promote inflammation, depending upon the disease syndrome, in vivo. This study was undertaken to evaluate the potential significance of strength of biofilm formation by clinical bovine mastitis -associated S. aureus in mammary tissue damage by using a mouse mastitis model. Two S. aureus strains of the same capsular phenotype with different biofilm forming strengths were used to non-invasively infect mammary glands of lactating mice. Biofilm forming potential of these strains were determined by tissue culture plate method, ica typing and virulence gene profile per detection by PCR. Delivery of the infectious dose of S. aureus was directly through the teat lactiferous duct without invasive scraping of the teat surface. Both bacteriological and histological methods were used for analysis of mammary gland pathology of mice post - infection. Histopathological analysis of the infected mammary glands revealed that mice inoculated with the strong biofilm forming S. aureus strain produced marked acute mastitic lesions, showing profuse infiltration predominantly with neutrophils, with evidence of necrosis in the affected mammary glands. In contrast, the damage was significantly less severe in mammary glands of mice infected with the weak biofilm-forming S. aureus strain. Although both IL-1β and TNF-α inflammatory biomarkers were produced in infected mice, level of TNF-α produced was significantly higher (p<0.05) in mice inoculated with strong biofilm forming S. aureus than the weak biofilm forming strain. This finding suggests an important role of TNF-α in mammary gland pathology post - infection with strong biofilm-forming S. aureus in the acute mouse mastitis model, and offers an opportunity for the development of novel strategies for reduction of mammary tissue damage, with or without use of antimicrobials and/or anti-inflammatory compounds for the treatment of bovine mastitis.
28129375	0	13	Mammary Gland	T023	C0929301
28129375	38	53	Acute Infection	T047	C0275518
28129375	59	65	Strong	T080	C0442821
28129375	73	77	Weak	T080	C1762617
28129375	78	93	Biofilm Forming	T043	C1325881
28129375	94	115	Staphylococcus aureus	T007	C0038172
28129375	116	131	Bovine Mastitis	T047	C0024895
28129375	132	140	Isolates	T123	C1764827
28129375	144	155	Pilot Study	T062	C0031928
28129375	162	174	Non-Invasive	T169	C0205303
28129375	175	189	Mouse Mastitis	T047	C1522044
28129375	190	195	Model	T050	C0012644
28129375	196	213	Biofilm formation	T043	C1325881
28129375	217	238	Staphylococcus aureus	T007	C0038172
28129375	255	264	virulence	T038	C0042765
28129375	303	309	induce	T169	C0205263
28129375	310	342	persistent antibiotic resistance	T032	C0949285
28129375	351	363	phagocytosis	T043	C0031308
28129375	375	384	attenuate	T052	C0599946
28129375	388	395	promote	T052	C0033414
28129375	396	408	inflammation	T046	C0021368
28129375	429	445	disease syndrome	T047	C0012634
28129375	447	454	in vivo	T082	C1515655
28129375	536	553	biofilm formation	T043	C1325881
28129375	557	565	clinical	T080	C0205210
28129375	566	581	bovine mastitis	T047	C0024895
28129375	594	603	S. aureus	T007	C0038172
28129375	607	614	mammary	T023	C0006141
28129375	615	628	tissue damage	T037	C0010957
28129375	640	654	mouse mastitis	T047	C1522044
28129375	655	660	model	T050	C0012644
28129375	666	675	S. aureus	T007	C0038172
28129375	676	683	strains	T001	C1518614
28129375	696	704	capsular	T082	C0205151
28129375	705	714	phenotype	T032	C0031437
28129375	730	745	biofilm forming	T043	C1325881
28129375	746	755	strengths	T078	C0808080
28129375	769	783	non-invasively	T169	C0205303
28129375	791	805	mammary glands	T023	C0929301
28129375	809	818	lactating	T033	C2828358
28129375	819	823	mice	T015	C1522424
28129375	825	840	Biofilm forming	T043	C1325881
28129375	841	850	potential	T080	C3245505
28129375	860	867	strains	T001	C1518614
28129375	887	914	tissue culture plate method	T059	C0040284
28129375	931	940	virulence	T038	C0042765
28129375	971	974	PCR	T063	C0032520
28129375	992	1007	infectious dose	T081	C1881203
28129375	1011	1020	S. aureus	T007	C0038172
28129375	1046	1050	teat	T023	C0222632
28129375	1051	1067	lactiferous duct	T023	C0222613
28129375	1076	1084	invasive	T080	C0205281
28129375	1085	1113	scraping of the teat surface	T061	C0405377
28129375	1120	1135	bacteriological	T059	C0004642
28129375	1140	1160	histological methods	T059	C0019637
28129375	1175	1183	analysis	T062	C0936012
28129375	1187	1200	mammary gland	T023	C0929301
28129375	1201	1210	pathology	T169	C0205469
28129375	1214	1218	mice	T015	C1522424
28129375	1219	1223	post	T079	C0687676
28129375	1226	1235	infection	T046	C3714514
28129375	1237	1254	Histopathological	T169	C0243140
28129375	1255	1263	analysis	T062	C0936012
28129375	1271	1279	infected	T033	C0439663
28129375	1280	1294	mammary glands	T023	C0929301
28129375	1309	1313	mice	T015	C1522424
28129375	1314	1324	inoculated	T061	C2987620
28129375	1334	1340	strong	T080	C0442821
28129375	1341	1356	biofilm forming	T043	C1325881
28129375	1357	1366	S. aureus	T007	C0038172
28129375	1367	1373	strain	T001	C1518614
28129375	1390	1404	acute mastitic	T047	C0149613
28129375	1405	1412	lesions	T033	C0221198
28129375	1430	1442	infiltration	T046	C0332448
28129375	1462	1473	neutrophils	T025	C0027950
28129375	1492	1500	necrosis	T042	C0027540
28129375	1517	1531	mammary glands	T023	C0929301
28129375	1550	1556	damage	T037	C0010957
28129375	1590	1604	mammary glands	T023	C0929301
28129375	1608	1612	mice	T015	C1522424
28129375	1613	1621	infected	T033	C0439663
28129375	1631	1635	weak	T080	C1762617
28129375	1636	1651	biofilm-forming	T043	C1325881
28129375	1652	1661	S. aureus	T007	C0038172
28129375	1662	1668	strain	T001	C1518614
28129375	1684	1689	IL-1β	T116,T129	C0021753
28129375	1694	1699	TNF-α	T116,T129	C1456820
28129375	1700	1712	inflammatory	T169	C0333348
28129375	1713	1723	biomarkers	T201	C0005516
28129375	1741	1749	infected	T033	C0439663
28129375	1750	1754	mice	T015	C1522424
28129375	1765	1770	TNF-α	T116,T129	C1456820
28129375	1817	1821	mice	T015	C1522424
28129375	1822	1832	inoculated	T061	C2987620
28129375	1838	1844	strong	T080	C0442821
28129375	1845	1860	biofilm forming	T043	C1325881
28129375	1861	1870	S. aureus	T007	C0038172
28129375	1880	1884	weak	T080	C1762617
28129375	1885	1900	biofilm forming	T043	C1325881
28129375	1901	1907	strain	T001	C1518614
28129375	1914	1921	finding	T033	C0243095
28129375	1952	1957	TNF-α	T116,T129	C1456820
28129375	1961	1974	mammary gland	T023	C0929301
28129375	1975	1984	pathology	T169	C0205469
28129375	1985	1989	post	T079	C0687676
28129375	1992	2001	infection	T046	C3714514
28129375	2007	2013	strong	T080	C0442821
28129375	2014	2029	biofilm-forming	T043	C1325881
28129375	2030	2039	S. aureus	T007	C0038172
28129375	2047	2067	acute mouse mastitis	T047	C0149613
28129375	2068	2073	model	T050	C0012644
28129375	2145	2154	reduction	T061	C0441610
28129375	2158	2165	mammary	T023	C0006141
28129375	2166	2179	tissue damage	T037	C0010957
28129375	2204	2218	antimicrobials	T121	C1136254
28129375	2226	2253	anti-inflammatory compounds	T121	C0003209
28129375	2262	2271	treatment	T061	C0087111
28129375	2275	2290	bovine mastitis	T047	C0024895